An award of $76 million may not sound like much in the big-dollar world of pharma, but for a branded drug company, it always feels good to win one against a generic drugmaker that has jumped the gun with a generic. That is how much a court says AstraZeneca should be paid by Apotex.
Forty-five women are seeking $800 million (U.S. $778.8 million) in a class-action lawsuit filed Friday, claiming a packaging foul-up by Apotex led them to take placebos instead of the active birth control pills.
It has been a particularly bad few days for Hospira, with both the company and the FDA alerting healthcare providers of problems with multiple lots of its drugs. That was in addition to an alert for one of its medical products.
Risk-management plans may be a burden for new drug launches, but they're proving to be a weapon against generic competition, too. As the New York Times reports, generics makers can't buy the supplies they need to knock off a product, thanks to REMS restrictions. So, they have to resort to asking branded drugmakers for supplies--and some of those companies aren't cooperating.
The generic drug manufacturer, which for nearly two years had its products banned from the U.S., has received a warning letter for two of its in Canada plants, one in Ontario and one in Toronto that has received a warning letter before.
Even as the clock is ticking down on the patent for its super blockbuster Singulair, Merck ($MRK) got smacked Friday with a negative decision in its battle with genericmaker Apotex over Merck's blockbuster Nasonex spray.
Plavix is a blood thinner from Bristol-Myers Squibb ($BMY). Generic Plavix is a Bristol-Myers profits thinner that is going to be produced by just about everybody and their brother.
Unigene Laboratories can hold on to its patent for Fortical, after the Supreme Court denied Apotex's petition this week.
Bad news coming out of Canada for Apotex. Canadian regulators are informing hypertensive patients the drugmaker is conducting a voluntary recall of one lot of Apo-Ramipril 5-mg capsules.
Apotex claims in a filing that the FDA "decimated" its business by issuing an import ban against drugs made at two of its Canadian facilities.